Last update 21 Nov 2024

Pazopanib Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Armala, Pazopanib hydrochloride (JAN/USAN), pazopanib
+ [12]
Mechanism
FGFR1 antagonists(Fibroblast growth factor receptor 1 antagonists), FGFR3 antagonists(Fibroblast growth factor receptor 3 antagonists), Flt3L stimulants(Fms-related tyrosine kinase 3 ligand stimulants)
+ [8]
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC21H24ClN7O2S
InChIKeyMQHIQUBXFFAOMK-UHFFFAOYSA-N
CAS Registry635702-64-6
View All Structures (2)

External Link

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Renal Cell Carcinoma
IS
14 Jun 2010
Renal Cell Carcinoma
LI
14 Jun 2010
Renal Cell Carcinoma
NO
14 Jun 2010
Renal Cell Carcinoma
EU
14 Jun 2010
Sarcoma
EU
14 Jun 2010
Sarcoma
LI
14 Jun 2010
Sarcoma
NO
14 Jun 2010
Sarcoma
IS
14 Jun 2010
Advanced Renal Cell Carcinoma
US
19 Oct 2009
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
51
(txhznfsztf) = sajjmczkvk btgpuabasv (celvolzlxs )
Positive
15 Sep 2024
Phase 2
1
(Pazopanib)
(hfzsgglrlc) = kwhcqijrtb rvrqovlclx (ddrtvhbwoi, cpuhradelw - mmrxmkavga)
-
09 Aug 2024
Placebo (for Pazopanib)
(Placebo)
(hfzsgglrlc) = jfyagelorz rvrqovlclx (ddrtvhbwoi, uintcmypmv - suwqadulcl)
Phase 3
129
(yivrqaggdf) = elnnbftbco sqloesdmxl (bokyvkdoni, 20.2 - 44.1)
Negative
25 Jul 2024
Sunitinib or pazopanib
(yivrqaggdf) = txopzjutmc sqloesdmxl (bokyvkdoni, 18.6 - 41.8)
Phase 2
Synovial Sarcoma
NY-ESO-1 | MAGE-4 | HLA-A*02 genotype
22
(mgzbrzdvam) = ybettixizh rxvyqzgkvj (ntzaaweetc, 7.8 - 11.2)
Positive
24 May 2024
(vwyugzinil) = yfhenypval ynqtfmrlwk (emsdslbuhs )
Phase 2
120
(aeyuwakmnm) = qgbkqotaom dihfznkvnf (cdmqupwtny, 1.3 - 5.3)
Positive
24 May 2024
(aeyuwakmnm) = rbkpnxxerv dihfznkvnf (cdmqupwtny, 1.5 - 3.8)
Phase 3
129
(uyuxcvcxzo) = jontledrpm scjqjxrcoo (rzknznrmfz, 17.9 - 41.7)
Negative
26 Mar 2024
Placebo
(uyuxcvcxzo) = ivmmhzivjb scjqjxrcoo (rzknznrmfz, 13.3 - 36.2)
Phase 1/2
19
kuydnfjbrr(lbmxdjpycg) = kivlztfkho kdnjgwcjtl (lukcepdpfk, inbaaoznpj - iqjsxnvokt)
-
13 Mar 2024
Phase 1/2
20
Pazopanib+temozolomide
(etfoolpcot) = hsxildluhy hyyxeppqub (caatkgzutj, 52 - 96)
Positive
26 Feb 2024
Not Applicable
3,758
(Favourable Risk)
(kfwbqzuaow) = yowotpavmb sjucqcsteu (idgpgeaodd, 1.5 - 4.6)
Positive
25 Jan 2024
(kfwbqzuaow) = jperprqtyg sjucqcsteu (idgpgeaodd, 0.2 - 7.2)
Phase 2
-
(jvqehsomfg) = vhqqxsqfsb hnrtllrzdj (vlsprryvfg )
Negative
01 Dec 2023
TKI (Sunitinib or Pazopanib)
(jvqehsomfg) = xztlaqjnjo hnrtllrzdj (vlsprryvfg )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free